Prescription drug · ANDA
Terazosin NDC 71335-3059
Terazosin hydrochloride 2 mg/1 · Capsule · Oral · Bryant Ranch Prepack
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71335-3059-1 | 71335305901 | 30 CAPSULE in 1 BOTTLE (71335-3059-1)Marketed from Feb 6, 2026 | |
| 71335-3059-2 | 71335305902 | 90 CAPSULE in 1 BOTTLE (71335-3059-2)Marketed from Feb 6, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Terazosin
- Generic name (nonproprietary)
- terazosin
- Active ingredients
- Terazosin hydrochloride — 2 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Bryant Ranch Prepack
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 075667
- Marketing start
- Listing expires
- Other FDA classes
- Adrenergic alpha-Antagonists (Mechanism)
- Identifiers
- Product ID 71335-3059_be7839c5-4321-43b7-8e9a-4f06cd8b9e99SPL ID be7839c5-4321-43b7-8e9a-4f06cd8b9e99SPL set ID 5c55d942-35c1-46f6-af89-2a0f68f3ea99RxCUI 313217UNII D32S14F082
- Pharmacologic class
- alpha-Adrenergic Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471335305901followed by a unit qualifier and the quantityPackage 71335-3059-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules. The long-term effects of terazosin on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin capsules are also indicated for the treatment of hypertension. It can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 075667
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Terazosin | Terazosin hydrochloride 5 mg/1 | CapsuleOral | Bionpharma Inc. | 69452-332 |
| Terazosin | Terazosin hydrochloride 1 mg/1 | CapsuleOral | Bionpharma Inc. | 69452-330 |
| Terazosin | Terazosin hydrochloride 2 mg/1 | CapsuleOral | Bionpharma Inc. | 69452-331 |
| Terazosin | Terazosin hydrochloride 10 mg/1 | CapsuleOral | Bryant Ranch Prepack | 71335-3123 |
| Terazosin | Terazosin hydrochloride 5 mg/1 | CapsuleOral | Bryant Ranch Prepack | 71335-3131 |
| Terazosin | Terazosin hydrochloride 10 mg/1 | CapsuleOral | Bionpharma Inc. | 69452-333 |
| Terazosin | Terazosin hydrochloride 2 mg/1 | CapsuleOral | REMEDYREPACK INC. | 70518-4545 |
| Terazosin | Terazosin hydrochloride 2 mg/1 | CapsuleOral | Preferred Pharmaceuticals Inc. | 68788-4064 |